Kurs & Likviditet
-1,21%
|
0,69 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2024-10-24 | Kvartalsrapport 2024-Q3 |
2024-08-16 | Kvartalsrapport 2024-Q2 |
2024-04-25 | Kvartalsrapport 2024-Q1 |
2024-04-25 | Ordinarie utdelning MEDI 4.50 NOK |
2024-04-24 | Årsstämma 2024 |
2024-02-29 | Bokslutskommuniké 2023 |
2023-10-27 | Kvartalsrapport 2023-Q3 |
2023-08-31 | Kvartalsrapport 2023-Q2 |
2023-04-25 | Kvartalsrapport 2023-Q1 |
2023-04-25 | Ordinarie utdelning MEDI 4.50 NOK |
2023-04-24 | Årsstämma 2023 |
2023-03-01 | Bokslutskommuniké 2022 |
2022-10-28 | Kvartalsrapport 2022-Q3 |
2022-08-23 | Kvartalsrapport 2022-Q2 |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-04-28 | Ordinarie utdelning MEDI 3.75 NOK |
2022-04-27 | Årsstämma 2022 |
2022-02-25 | Bokslutskommuniké 2021 |
2021-10-22 | Kvartalsrapport 2021-Q3 |
2021-08-13 | Kvartalsrapport 2021-Q2 |
2021-04-28 | Ordinarie utdelning MEDI 3.00 NOK |
2021-04-27 | Kvartalsrapport 2021-Q1 |
2021-04-27 | Årsstämma 2021 |
2021-02-26 | Bokslutskommuniké 2020 |
2020-10-22 | Kvartalsrapport 2020-Q3 |
2020-10-22 | Ordinarie utdelning MEDI 2.75 NOK |
2020-08-14 | Kvartalsrapport 2020-Q2 |
2020-04-29 | Kvartalsrapport 2020-Q1 |
2020-04-28 | Årsstämma 2020 |
2020-04-03 | Extra Bolagsstämma 2020 |
2020-02-28 | Bokslutskommuniké 2019 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-20 | Kvartalsrapport 2019-Q2 |
2019-04-25 | Ordinarie utdelning MEDI 2.25 NOK |
2019-04-25 | Kvartalsrapport 2019-Q1 |
2019-04-24 | Årsstämma 2019 |
2019-03-15 | Bokslutskommuniké 2018 |
2019-02-27 | Bokslutskommuniké 2018 |
2018-10-25 | Kvartalsrapport 2018-Q3 |
2018-08-15 | Kvartalsrapport 2018-Q2 |
2018-04-26 | Ordinarie utdelning MEDI 2.00 NOK |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-04-25 | Årsstämma 2018 |
2018-02-15 | Bokslutskommuniké 2017 |
2017-10-24 | Kvartalsrapport 2017-Q3 |
2017-08-24 | Kvartalsrapport 2017-Q2 |
2017-04-27 | Ordinarie utdelning MEDI 1.75 NOK |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-04-26 | Årsstämma 2017 |
2017-02-17 | Bokslutskommuniké 2016 |
2016-10-19 | Kvartalsrapport 2016-Q3 |
2016-08-24 | Kvartalsrapport 2016-Q2 |
2016-04-20 | Ordinarie utdelning MEDI 1.65 NOK |
2016-04-19 | Årsstämma 2016 |
2016-03-01 | Bokslutskommuniké 2015 |
2015-10-23 | Kvartalsrapport 2015-Q3 |
2015-08-19 | Kvartalsrapport 2015-Q2 |
2015-04-24 | Ordinarie utdelning MEDI 1.40 NOK |
2015-04-24 | Kvartalsrapport 2015-Q1 |
2015-04-23 | Årsstämma 2015 |
2015-02-26 | Bokslutskommuniké 2014 |
2014-10-23 | Kvartalsrapport 2014-Q3 |
2014-08-20 | Kvartalsrapport 2014-Q2 |
2014-04-25 | Kvartalsrapport 2014-Q1 |
2014-04-24 | Ordinarie utdelning |
2014-04-23 | Årsstämma 2014 |
2014-02-20 | Bokslutskommuniké 2013 |
2013-10-24 | Kvartalsrapport 2013-Q3 |
2013-08-20 | Kvartalsrapport 2013-Q2 |
2013-04-26 | Ordinarie utdelning |
2013-04-25 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-03-08 | Kapitalmarknadsdag 2013 |
2013-02-28 | Bokslutskommuniké 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-08-24 | Kvartalsrapport 2012-Q2 |
2012-04-27 | Kvartalsrapport 2012-Q1 |
2012-04-27 | Ordinarie utdelning |
2012-04-26 | Årsstämma 2012 |
2012-02-22 | Bokslutskommuniké 2011 |
2011-10-28 | Kvartalsrapport 2011-Q3 |
2011-08-24 | Kvartalsrapport 2011-Q2 |
2011-04-29 | Ordinarie utdelning |
2011-04-29 | Kvartalsrapport 2011-Q1 |
2011-04-28 | Årsstämma 2011 |
2011-02-18 | Bokslutskommuniké 2010 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Medicinteknik |
2021-06-08 10:02:15
(Oslo, 8th of June 2021) Medistim ASA (OSE: MEDI) is a niche market leader
within ultrasound technology with headquarters in Oslo, Norway. Medistim
develops and commercializes medical equipment for use within cardiac, vascular
and transplant surgery. Today, Medistim announces the launch of the Pay Per
Procedure (PPP) functionality to our latest MiraQTM platform in the US market.
Medistim utilizes several business models to effectively reach different
segments of the US market. In addition to traditional capital investments and
purchase of consumables, hospitals can choose to enter leasing agreements or Pay
Per Procedure (PPP). The PPP functionality has proven to be a popular option
with our previous generation of medical device (VeriQTM and VeriQCTM and will
now also be available to our MiraQ customers.
"Some of our largest customers in the USA are greatly appreciating the PPP model
with their current VeriQTM platform and Medistim wants to make their transition
to the latest platform MiraQTM as smooth as possible," says Medistim President
and CEO, Kari E. Krogstad. "The US market is key to Medistim's success, making
up about 1/3 of the global potential market, and it is our priority to respond
to our customers' preferences."
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
and Norway, in addition to the about 50 distributors in Europe, Asia, Middle
East, Africa, Canada and South America. For more information, visit the
Medistim home page: www.medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com